Results 71 to 80 of about 22,404 (220)

Electron scattering from molecules and molecular aggregates of biological relevance [PDF]

open access: yes, 2017
In this Topical Review we survey the current state of the art in the study of low energy electron collisions with biologically relevant molecules and molecular clusters.
Allan M   +33 more
core   +1 more source

On why cancer cells require a great amount of glucose

open access: yesQuantitative Biology, Volume 14, Issue 2, June 2026.
Abstract The traditional thinking has been that cancer cells require a great amount of glucose to support their rapid growth, but the reality may be different. We have previously demonstrated that all cancer cells in The Cancer Genome Atlas harbor persistent Fenton reactions in their cytosol, which generate OH− ${\text{OH}}^{-}$ and ultimately kill the
Xuechen Mu   +6 more
wiley   +1 more source

Engineering a Bifunctional Fusion Purine/Pyrimidine Nucleoside Phosphorylase for the Production of Nucleoside Analogs

open access: yesBiomolecules
Nucleoside phosphorylases (NPs) are pivotal enzymes in the salvage pathway, catalyzing the reversible phosphorolysis of nucleosides to produce nucleobases and α-D-ribose 1-phosphate.
Daniel Hormigo   +4 more
doaj   +1 more source

Fluorescent Nanoparticles Synthesized from DNA, RNA, and Nucleotides

open access: yesNanomaterials, 2021
Ubiquitous on Earth, DNA and other nucleic acids are being increasingly considered as promising biomass resources. Due to their unique chemical structure, which is different from that of more common carbohydrate biomass polymers, materials based on ...
Maofei Wang   +3 more
doaj   +1 more source

Synthesis and complementary self-association of novel lipophilic π-conjugated nucleoside oligomers [PDF]

open access: yes, 2015
The following article appeared in Organic and Biomolecular Chemistry 13.15 (2015): 4506-4513 and may be found at http://dx.doi.org/10.1039/c5ob00098j, reproduced by permission of The Royal Society of ChemistryA series of lipophilic nucleosides ...
Camacho García, J.   +2 more
core   +2 more sources

Impact of Underlying Liver Disease on the Risk and Prognostic Factors of Breast Cancer Liver Metastases: A Retrospective Multicenter Cohort Study

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Objective To examine factors influencing breast cancer liver metastases (BCLM) and assess the impact of underlying liver diseases (nonalcoholic fatty liver and HBsAg infection) on BCLM development. Methods Patients diagnosed with breast cancer at four affiliated hospitals in China between 2014 and 2024 were included.
Xiaowen Wang   +16 more
wiley   +1 more source

Synthesis and Biological Properties of 5-(1H-1,2,3-Triazol-4-yl)isoxazolidines: A New Class of C-Nucleosides

open access: yesMolecules, 2015
A novel series of C-nucleosides, featuring the presence of a 1,2,3-triazole ring linked to an isoxazolidine system, has been designed as mimetics of the pyrimidine nucleobases.
Salvatore V. Giofrè   +7 more
doaj   +1 more source

RNA Modifications: Current Understandings and Future Perspectives

open access: yesMedComm, Volume 7, Issue 5, May 2026.
Types of RNA modification. We have summarized the currently common types of RNA modifications, including ac4C, m6A, m1A, m5C, m3C, m7G, and ψ, and visually characterized their features through structural formulas. The characteristic structures are marked with a background color different from the background color.
Shiyu Xiao   +7 more
wiley   +1 more source

Phosphonated Carbocyclic 2'-Oxa-3'-azanucleosides as New Antiretroviral Agents [PDF]

open access: yes, 2007
Phosphonated carbocyclic 2¢-oxa-3¢-azanucleosides have been synthesized and tested for their antiretroviral activity. The obtained results have shown that some of the compounds were as powerful as azydothymidine in inhibiting the reverse transcriptase ...
Balestrieri, E   +10 more
core   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy